| Colorectal Cancer is one of common gastrointestinal malignant tumor,With the change of the life style, the diet and the environment, there is a growing tendency for the incidence and mortality of colorectal cancer in the world. The treatment of colorectal cancer is comprehensive therapy that mainly consists of surgical excision, However, radical surgical resection rate is low, less than 5 percent, in addition there are 50 percent of the patients that a recurrence or metastasis happens in the five years.There are 1/4 to 1/3 of patients at the time of diagnosis is already late, radical surgery can not do anything. Therefore, adjuvant chemotherapy in patients with advanced colorectal cancer treatment occupies the important position, [5-FU+LV] has been colorectal cancer chemotherapy is the mainstream model, however, its efficiency and the median survival time is not satisfactory.In recent years, new targeted therapy drugs such as cetuximab, bevacizumab are applied, the survival of patients with colorectal cancer have improved significantly, The median survival time was extended to 20 months. How to choose the best treatment options to improve the quality of life, and effectively extend the survival time is needed in clinical practice thought.Currently the treatment of colorectal cancer is FOLFOX(platinum-containing) or FOLFIRI (containing camptothecin) as the first-line chemotherapy, as a second line in the treatment of advanced colorectal cancer, there are only the efficiency of 21.1% and 14.1%.The retrospective analysis of the china-Japan union Hospital of Jilin University from January,2002 to February,2008 sustains the integrity of the information treated metastatic or recurrent advanced colorectal cancer patients in 41 cases, 23 cases are [Oxaliplatin+ Capecitabine], 18 cases are [HCPT+Capecitabine], chemotherapy side effects observed, the patients can be evaluated after at least two cycles of chemotherapy later, imaging examination, and after four weeks to confirm the results of statistical effect of the two groups is efficient, the primary endpoint for efficacy evaluation, a secondary endpoint for TTP and PFS, were analyzed.The results show: oxaliplatin group (A) of 36.4% for the RR, HCPT group (B) RR to 18.8%, A, B Comparison of the two groups recently no significant difference (P> 0.05 ); Efficient treatment of patients with colon cancer (RR) was 33.3%, effective in patients with colorectal cancer (RR) was 23.5%, compared with no statistical difference (P> 0.05); patients with liver metastasis RR of 27.8%, lung metastasis Patients with RR was 25.0%, RR for the transfer of other parts of 18.5%. The X2 test P> 0.05, no statistical difference between patients with newly diagnosed RR was 66.7%, re-treated patients with RR for 11.5 percent. Contrast the two groups P<0.05, a significant difference; A, B two cases of toxicity rates were 54.5% and 6.3%, the X2 test P<0.05, a significant difference, other adverse reactions had no statistical difference . Group B patients with the incidence of diarrhea (68.8%) than group A (36.4%) nearly doubled, but the X2 test (P>0.05), there is no statistically significant difference between the two groups, such as combining Vanhoefer summary of the 17 cases 39 cases of treatment information, B group of patients withâ…¢orâ…£degree of non-hematological adverse reactions is diarrhea. Survival Analysis: A group of time to progression(TTP) is 6.9 months, the median progression free survival(PFS) is 6.9 months; B group in time to progression(TTP) is 7.4 months, the median progression free survival(PFS)is 7.4 months. There was no significant difference(P>0.05).To sum up, oxaliplatin, or HCPT plus capecitabine for the treatment of metastatic or recurrent advanced colorectal cancer (â…£period) is effective, the two are quite efficient, in the survival analysis there is no significant difference, Efficient is related to chemotherapy whether or not in the past, and tumor metastasis may be related to the site, with the primary tumor is not related to the colon or rectum. [Oxaliplatin+ Capecitabine] the toxicity of the programme is mainly peripheral nerve toxicity,[HCPT+Capecitabine] programme while the more common diarrhea. The foundation has been suffering from neuropathy patients, should choose to HCPT-based plus programmes;basis for a bowel dysfunction in patients, particularly after intestinal disorder patients,the recommendations should be Oxaliplatin Consisting mainly of joint programmes which are more secure. |
